SCHEMBL4814536

SCHEMBL4814536

CCCCCCc1nc(-c2ccc(-c3ccccc3)cc2)c[nH]1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
DHFR P00374 1/20 0.42
HSD11B1 P28845 1/20 0.41
TLR8 Q9NR97 2/20 0.40
KCNH2 Q12809 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
STAT1 P42224 1/20 0.39
RAB9A P51151 1/20 0.39
GSK3B P49841 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
GCGR P47871 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11297462 0.97 GPR84 (0.44) GPR84SMN1; SMN2MAPTTP53DHFR
SCHEMBL2946753 0.97 GPR84 (0.44) GPR84SMN1; SMN2MAPTTP53DHFR
SCHEMBL6618330 0.91 GSK3B (0.44) GPR84SMN1; SMN2MAPTTP53HSD11B1
Ammonia Solution, Strong SCHEMBL27564785 0.89 GSK3B (0.43) GPR84SMN1; SMN2MAPTTP53HSD11B1
Benzylamine SCHEMBL28750130 0.88 TLR8 (0.42) GPR84SMN1; SMN2MAPTTP53DHFR
SCHEMBL1926476 0.87 SIGMAR1 (0.48) MAPTTLR8NPC1ALDH1A1STAT1
SCHEMBL1917870 0.84 ADORA3 (0.50) SMN1; SMN2MAPTTP53TLR8NPC1
SCHEMBL8016347 0.84 TLR8 (0.47) SMN1; SMN2MAPTTLR8ALDH1A1RAB9A
SCHEMBL27815847 0.83 HSD11B1 (0.50) GPR84MAPTTP53HSD11B1KCNH2
SCHEMBL27835295 0.83 HSD11B1 (0.50) GPR84MAPTTP53HSD11B1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402602-B2 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 2008-07-22 US claimed
US-20070099975-A1 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2007-05-03 US claimed
US-7157483-B2 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-01-02 US claimed
US-20060069146-A1 Imidazole derivatives modulating the sodium channels SCRAS 2006-03-30 US claimed
EP-1401432-B1 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS SOD CONSEILS RECH APPLIC (FR) 2005-09-14 EP claimed
JP-2005500297-A 2005-01-06 JP claimed
EP-1401432-A2 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2004-03-31 EP claimed
WO-2002102375-A2 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2002-12-27 WO claimed
US-7402602-B2 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 2008-07-22 US disclosed
US-20070099975-A1 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2007-05-03 US disclosed
US-7157483-B2 Imidazole derivatives modulating the sodium channels SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-01-02 US disclosed
US-20060069146-A1 Imidazole derivatives modulating the sodium channels SCRAS 2006-03-30 US disclosed
EP-1401432-B1 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS SOD CONSEILS RECH APPLIC (FR) 2005-09-14 EP disclosed
US-20040198792-A1 Imidazole derivatives modulating the sodium channels IPSEN PHARMA S.A.S. (FR) 2004-10-07 US disclosed
EP-1401432-A2 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2004-03-31 EP disclosed
WO-2002102375-A2 IMIDAZOLE DERIVATIVES FOR MODULATING SODIUM CHANNELS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198792-A1 Imidazole derivatives modulating the sodium channels SCN1A, SCN1B, TRPV1 GPR84 1535/4885SMN1; SMN2 718/4885MAPT 474/4885
US-20070099975-A1 Imidazole derivatives modulating the sodium channels SCN2B, KCNJ2, SCN1B GPR84 1788/4885SMN1; SMN2 968/4885MAPT 2473/4885
US-20060069146-A1 Imidazole derivatives modulating the sodium channels SCN1B, SCN1A, SCN2B GPR84 2060/4885SMN1; SMN2 441/4885MAPT 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.